JP2021536244A5 - - Google Patents

Info

Publication number
JP2021536244A5
JP2021536244A5 JP2021511542A JP2021511542A JP2021536244A5 JP 2021536244 A5 JP2021536244 A5 JP 2021536244A5 JP 2021511542 A JP2021511542 A JP 2021511542A JP 2021511542 A JP2021511542 A JP 2021511542A JP 2021536244 A5 JP2021536244 A5 JP 2021536244A5
Authority
JP
Japan
Prior art keywords
target rna
vector according
vector
sequence complementary
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021511542A
Other languages
English (en)
Japanese (ja)
Other versions
JP7720623B2 (ja
JP2021536244A (ja
JP7720623B6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050095 external-priority patent/WO2020051555A1/en
Publication of JP2021536244A publication Critical patent/JP2021536244A/ja
Publication of JP2021536244A5 publication Critical patent/JP2021536244A5/ja
Publication of JP7720623B2 publication Critical patent/JP7720623B2/ja
Application granted granted Critical
Publication of JP7720623B6 publication Critical patent/JP7720623B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511542A 2018-09-06 2019-09-06 遺伝子操作されたadarのリクルートを介したrna及びdna塩基の編集 Active JP7720623B6 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862728007P 2018-09-06 2018-09-06
US62/728,007 2018-09-06
US201862766433P 2018-10-17 2018-10-17
US62/766,433 2018-10-17
US201862773150P 2018-11-29 2018-11-29
US201862773146P 2018-11-29 2018-11-29
US62/773,146 2018-11-29
US62/773,150 2018-11-29
US201862780241P 2018-12-15 2018-12-15
US62/780,241 2018-12-15
PCT/US2019/050095 WO2020051555A1 (en) 2018-09-06 2019-09-06 Rna and dna base editing via engneered adar recruitment

Publications (4)

Publication Number Publication Date
JP2021536244A JP2021536244A (ja) 2021-12-27
JP2021536244A5 true JP2021536244A5 (https=) 2022-10-19
JP7720623B2 JP7720623B2 (ja) 2025-08-08
JP7720623B6 JP7720623B6 (ja) 2025-09-18

Family

ID=69723301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511542A Active JP7720623B6 (ja) 2018-09-06 2019-09-06 遺伝子操作されたadarのリクルートを介したrna及びdna塩基の編集

Country Status (8)

Country Link
US (2) US20220010333A1 (https=)
EP (2) EP4332224A3 (https=)
JP (1) JP7720623B6 (https=)
CN (2) CN119193702A (https=)
AU (1) AU2019336793B2 (https=)
CA (1) CA3110998A1 (https=)
GB (1) GB2590880A (https=)
WO (1) WO2020051555A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612353A (zh) * 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
WO2019104094A2 (en) 2017-11-21 2019-05-31 The Regents Of The University Of California Fusion proteins and methods for site-directed genome editing
EP3956449B1 (en) 2019-04-15 2026-02-25 EdiGene Therapeutics (Beijing) Inc. Methods and compositions for editing rnas
EP3997229A4 (en) * 2019-07-12 2024-07-03 Peking University TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA
WO2021113264A1 (en) * 2019-12-02 2021-06-10 The Regents Of The University Of California Engineering circular guide rnas
WO2021113390A1 (en) * 2019-12-02 2021-06-10 Shape Therapeutics Inc. Compositions for treatment of diseases
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
US20230059753A1 (en) * 2019-12-09 2023-02-23 Astellas Pharma Inc. Antisense guide rna with added functional region for editing target rna
CN115777020A (zh) * 2020-04-22 2023-03-10 塑造治疗公司 使用snrna组分的组合物和方法
EP4158019A1 (en) * 2020-05-26 2023-04-05 Shape Therapeutics Inc. Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing
JP2023528039A (ja) * 2020-05-26 2023-07-03 シェイプ セラピューティクス インコーポレイテッド 改変環状ポリヌクレオチド
JP2023529316A (ja) * 2020-05-26 2023-07-10 シェイプ セラピューティクス インコーポレイテッド ゲノム編集のための組成物及び方法
US20230272379A1 (en) * 2020-07-06 2023-08-31 Edigene Therapeutics (Beijing ) Inc. Improved rna editing method
CN116209762A (zh) * 2020-07-30 2023-06-02 阿达尔克斯制药有限公司 Adar依赖性编辑组合物及其使用方法
WO2022046667A1 (en) * 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Cells and non-human animals engineered to express adar1 and uses thereof
WO2022078569A1 (en) * 2020-10-12 2022-04-21 Eberhard Karls Universität Tübingen Artificial nucleic acids for rna editing
JP2024500279A (ja) * 2020-11-11 2024-01-09 シェイプ セラピューティクス インコーポレイテッド Rna編集組成物及び使用方法
EP4256050A4 (en) * 2020-12-01 2025-01-22 Shape Therapeutics Inc. High throughput rna-editing screening methods
US20240150754A1 (en) * 2020-12-25 2024-05-09 Astellas Pharma Inc. Guide rna for editing polyadenylation signal sequence of target rna
CA3220338A1 (en) * 2021-05-25 2022-12-01 Yiannis SAVVA Engineered guide rnas and polynucleotides
WO2023278436A1 (en) * 2021-06-29 2023-01-05 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
EP4388089A4 (en) * 2021-08-18 2025-01-15 Peking University Engineered adar-recruiting rnas and methods of use thereof
AU2022337146A1 (en) 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components
JP2023040852A (ja) * 2021-09-10 2023-03-23 隆光 矢野 -1フレームシフトを誘導するための1本鎖核酸分子及び組成物
US20230167441A1 (en) * 2021-11-30 2023-06-01 Minghong Zhong Segmented Nucleic Acids
US20250115908A1 (en) * 2022-02-07 2025-04-10 The Regents Of The University Of California Method of interfering with repetitive rna
WO2023196853A1 (en) * 2022-04-05 2023-10-12 Astellas Gene Therapies, Inc. Compositions and methods for the treatment of muscular dystrophies
CN116732039B (zh) * 2023-08-03 2023-11-14 呈诺再生医学科技(北京)有限公司 一种促进rna序列在细胞内直接环化翻译的序列组合及其应用
CN117210435A (zh) * 2023-08-29 2023-12-12 苏州湃芮生物科技有限公司 一种用于调控rna甲基化修饰的编辑系统及其应用
CN121059628A (zh) * 2024-06-03 2025-12-05 时夕(广州)生物科技有限公司 调控RNA剪接的向导agRNA
WO2026080897A1 (en) * 2024-10-11 2026-04-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of chronic pain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FR2764387B1 (fr) * 1997-06-05 1999-07-23 Centre Nat Rech Scient Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
EP3234134B1 (en) * 2014-12-17 2020-05-27 ProQR Therapeutics II B.V. Targeted rna editing
CA3005245A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of alagille syndrome
CN109642231A (zh) * 2016-06-17 2019-04-16 博德研究所 Vi型crispr直向同源物和系统
WO2017220751A1 (en) * 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
WO2018208998A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9

Similar Documents

Publication Publication Date Title
JP2021536244A5 (https=)
Smeyne et al. Infection and risk of Parkinson’s disease
Pleasure et al. The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines
Kiyota et al. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders
JP2019089787A5 (https=)
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
MX2021012867A (es) Terapéutica de anticuerpos postraduccionalmente modificados completamente humanos.
BR112022015979A2 (pt) Vetores de terapia genética para tratamento de doenças cardíacas
JP2018523668A5 (https=)
JP2022505585A5 (https=)
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP2022066336A5 (https=)
JP2019525898A5 (https=)
JP2016538885A5 (https=)
JP2021513866A5 (https=)
JP2014517694A5 (https=)
CO2021016323A2 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
JP2016500519A5 (https=)
Sommer et al. Fostering poststroke recovery: towards combination treatments
JPWO2020059847A5 (https=)
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
JP2014511682A5 (https=)
JP2020527167A5 (https=)
JP2019505567A5 (https=)